ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference

Rhea-AI Summary

ImmunoGen, Inc. (Nasdaq: IMGN) announced that Dr. Anna Berkenblit, Chief Medical Officer, will participate in a panel discussion on ovarian cancer at the Canaccord Genuity Horizons in Oncology Virtual Conference. The event is scheduled for April 14, 2022, from 8:00 – 8:50 AM ET. A webcast of the panel will be available on the Company’s website, with a replay following the live event. ImmunoGen focuses on developing advanced antibody-drug conjugates (ADCs) aimed at improving cancer treatment outcomes.

Positive

• Participation in a relevant oncology panel may enhance visibility in the cancer treatment field.
• Ongoing commitment to developing advanced ADCs signals potential for innovation in cancer therapies.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Dr. Anna Berkenblit, Chief Medical Officer, will participate in the Reshaping Ovarian Cancer panel discussion at the upcoming Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for April 14, 2022 from 8:00 – 8:50am ET.

A webcast of the panel will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005315/en/

INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

FAQ

What is the significance of Dr. Anna Berkenblit's participation in the Canaccord Genuity Horizons in Oncology Virtual Conference?

Dr. Anna Berkenblit's participation highlights ImmunoGen's engagement in key discussions within the oncology field, potentially increasing the company's visibility and influence.

When is the Canaccord Genuity Horizons in Oncology Virtual Conference scheduled?

The conference is scheduled for April 14, 2022, from 8:00 – 8:50 AM ET.

How can I access the webcast of the oncology panel discussion?

The webcast will be available through the 'Investors and Media' section on ImmunoGen's website.

What does ImmunoGen focus on in its research and development?

ImmunoGen focuses on developing next-generation antibody-drug conjugates (ADCs) to improve cancer treatment outcomes.

What is the stock symbol for ImmunoGen?

The stock symbol for ImmunoGen is IMGN.